Use of venlafaxine in psychiatric disorders and climacteric syndrome: is a therapeutic bridge?

References

• Banger M. Affective syndrome during perimenopause. Maturitas 2002;15:13–18.
   Google Scholar
• Genazzani AR, Bernardi F, Pluchino N, Begliuomini S, Lenzi E, Casarosa E, Luisi M. Endocrinology of menopausal transition and its brain implications. CNS Spectr 2005;10:449–457.
   PubMed Web of Science ®Google Scholar
• Deecher D, Andree TH, Sloan D, Schechter LE. From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology 2008;33:3–17.
   PubMed Web of Science ®Google Scholar
• Rybaczyk LA, Bashaw MJ, Pathak DR Moody SM. An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology. BMC Womens Health 2005;20:5–12.
   Google Scholar
• Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 2009;206:345–354.
   PubMed Web of Science ®Google Scholar
• Cleare AJ, McGregor A, O’Keane V. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol (Oxf) 1995;43:713–719.
   PubMed Web of Science ®Google Scholar
• Ladd CO, Newport DJ, Ragan KA, Loughhead A, Stowe ZN. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005;22:94–97.
   PubMed Web of Science ®Google Scholar
• Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161–166.
   PubMed Web of Science ®Google Scholar
• Stearns V, Loprinzi CL. New therapeutic approaches for hot flashes in women. J Support Oncol 2003;1:11–21 discussion 14.
   PubMedGoogle Scholar
• Barlow DH. Venlafaxine for hot flushes. Lancet 2000;356:2025–2026.
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004;11:11–33.
   PubMed Web of Science ®Google Scholar
• Campagne DM. Venlafaxine and serious withdrawal symptoms: warning to drivers. MedGenMed 2005;7:22.
   PubMedGoogle Scholar
• Padala PR, Rapuri B, Padala KP. Alleviation of hot flashes with increase in venlafaxine dose prim care companion. J Clin Psychiatry 2007;9:70–71.
   Google Scholar
• Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S; Study 319 Investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238.e1–238.e10.
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Koivunen R, Sundström H, Bloigu R, Karjalainen E, Häivä-Mällinen L, Tapanainen JS. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18–26.
   PubMed Web of Science ®Google Scholar
• Carroll DG, Kelley KW. Use of antidepressants for management of hot flashes. Pharmacotherapy 2009;29:1357–1374.
   PubMed Web of Science ®Google Scholar
• ZUNG WW. A Self-Rating Depression Scale. Arch Gen Psychiatry 1965;12:63–70.
   PubMed Web of Science ®Google Scholar
• Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971;12:371–379.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Harnett Sheehan K, Janavs J, WeillerE, KeskinerA, Schinka J, Knapp E, Sheehan MF, Dunbar GC. The validity of the Mini International Neuropsychiatric Interview according to the SCID-P and its reliability. Eur Psychiatry 1997;12:232–241.
   Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–55.
   PubMed Web of Science ®Google Scholar
• Collegium internationale Psychiatriae Scalarum (CIPS). Internationale Skalen fur Psychiatrie. Weinheim: Beltz Verlag; 1998.
   Google Scholar
• Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry 1976;128:280–289.
   PubMed Web of Science ®Google Scholar
• Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001;62:523–529.
   PubMed Web of Science ®Google Scholar
• Frey BN, Lord C, Soares CN. Depression during menopausal transition: a review of treatment strategies and pathophysiological correlates. Menopause Int 2008;14:123–128.
   PubMedGoogle Scholar
• Warren MP. Missed symptoms of menopause. Int J Clin Pract 2007;61:2041–2050.
   PubMed Web of Science ®Google Scholar
• Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL, Cohen LS. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003;64:473–479.
   PubMed Web of Science ®Google Scholar
• Soares CN, Arsenio H, Joffe H, Bankier B, Cassano P, Petrillo LF, Cohen LS. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006;13:780–786.
   PubMed Web of Science ®Google Scholar
• Oishi A, Mochizuki Y, Otsu R, Inaba N. Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women. Biopsychosoc Med 2007;1:12.
   PubMedGoogle Scholar
• Joffe H, Soares CN, Petrillo LF, Viguera AC, Somley BL, Koch JK, Cohen LS. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007;68:943–950.
   PubMed Web of Science ®Google Scholar